JP2010024180A - Oil-in-water emulsion composition for promoting recovery of skin barrier function - Google Patents

Oil-in-water emulsion composition for promoting recovery of skin barrier function Download PDF

Info

Publication number
JP2010024180A
JP2010024180A JP2008187103A JP2008187103A JP2010024180A JP 2010024180 A JP2010024180 A JP 2010024180A JP 2008187103 A JP2008187103 A JP 2008187103A JP 2008187103 A JP2008187103 A JP 2008187103A JP 2010024180 A JP2010024180 A JP 2010024180A
Authority
JP
Japan
Prior art keywords
oil
extract
barrier function
skin barrier
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008187103A
Other languages
Japanese (ja)
Other versions
JP5642924B2 (en
Inventor
Nobuhide Tsuji
延秀 辻
Yuko Tate
優子 舘
Eri Ueda
恵利 上田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mikimoto Pharmaceutical Co Ltd
Original Assignee
Mikimoto Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mikimoto Pharmaceutical Co Ltd filed Critical Mikimoto Pharmaceutical Co Ltd
Priority to JP2008187103A priority Critical patent/JP5642924B2/en
Publication of JP2010024180A publication Critical patent/JP2010024180A/en
Application granted granted Critical
Publication of JP5642924B2 publication Critical patent/JP5642924B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Cosmetics (AREA)

Abstract

<P>PROBLEM TO BE SOLVED: To provide a preparation promptly recovering skin barrier function which is one of the various functions of the skin and is deteriorated by external stimuli or stresses such as exposure to UV or chemicals or internal factors such as aging. <P>SOLUTION: The oil-in-water emulsion composition for recovering skin barrier function is an emulsion which comprises an oil-soluble component containing ≥70% sterol ester, at least one surfactant and a water-soluble component and has an average particle size of ≤300 nm. The composition comprising at least one chosen from lecithin, polyglyceryl fatty acid ester and ceramide saccharide as the surfactant is particularly effective. <P>COPYRIGHT: (C)2010,JPO&INPIT

Description

本発明は、化粧品や医薬品として用いられる水中油型乳化組成物に関する。さらに詳しくは皮膚バリア機能回復促進に有効な水中油型乳化組成物に関する。   The present invention relates to an oil-in-water emulsion composition used as a cosmetic or pharmaceutical product. More specifically, the present invention relates to an oil-in-water emulsion composition effective for promoting the recovery of skin barrier function.

皮膚の機能は様々あるが、その1つにバリア機能があるが、紫外線や化学物質の外部からの刺激やストレスや老化等の内部要因によっても皮膚バリア機能が低下する。
皮膚バリア機能の回復にはセラミドやニコチン酸類(特許文献1参照)グリチルリチン或いはその誘導体やアスパラガスやブッチャーズブルームの抽出物(特許文献2参照)等が知られている。
化粧品等の分野ではステロールエステルは原料として使用されている。その一例は液晶構造を取るので外観上の美観や保湿性の高い化粧品として用いられている。(特許文献3参照)
特開平11−292765号公報 特開2000−053533号公報 特開平01−246209号公報
Although there are various skin functions, one of them has a barrier function, but the skin barrier function is also lowered by internal factors such as ultraviolet rays and chemical external stimuli, stress and aging.
Ceramide, nicotinic acids (see Patent Document 1), glycyrrhizin or its derivatives, asparagus, butcher's bloom extract (see Patent Document 2), and the like are known for recovery of the skin barrier function.
In fields such as cosmetics, sterol esters are used as raw materials. One example is a liquid crystal structure, which is used as a cosmetic product with high aesthetics and high moisture retention. (See Patent Document 3)
JP 11-292765 A JP 2000-053533 A Japanese Patent Laid-Open No. 01-246209

化粧品ですでに、皮膚バリア機能回復を目的としたものは存在するが、より優れた皮膚バリア機能回復能を有した化粧品を見出すことにある。   Although cosmetics already exist for the purpose of restoring the skin barrier function, it is to find a cosmetic having a better ability to restore the skin barrier function.

ステロールエステルを70%以上含む油溶性成分と、界面活性剤の1種または2種以上と水溶性成分からなる水中油型乳化物であって、平均粒子径が300nm以下にすることによって皮膚バリア機能回復能が非常に優れた製剤を得ることができた。(なお、本願においては%は重量%を示す)   An oil-in-water emulsion comprising an oil-soluble component containing 70% or more of a sterol ester, one or more surfactants, and a water-soluble component, and having an average particle size of 300 nm or less, the skin barrier function A preparation with very good recovery ability could be obtained. (In this application, “%” means “% by weight”)

まず、本発明に用いるステロールエステルは、コレステロール、ジヒドロコレステロール、ラノステロール、ジヒドロラノステロール、デスモステロール、スチグマステロール、シトステロール、カンペステロール、ブラシカステロール、エルゴステロール等のステロールと、炭素数2〜30の飽和または不飽和の分岐を有していてもよいさらにはヒドロキシ基を有していてもよいカルボン酸とのエステルである。 これの1種または2種以上を用いる。
これらのステロールエステルは油溶性成分の70%以上を占めるように配合する。その他油溶性成分には特に限定はない。
First, the sterol ester used in the present invention is a sterol such as cholesterol, dihydrocholesterol, lanosterol, dihydrolanosterol, desmosterol, stigmasterol, sitosterol, campesterol, brassicasterol, ergosterol, etc. It is an ester with a carboxylic acid which may have an unsaturated branch and may further have a hydroxy group. One or more of these are used.
These sterol esters are blended so as to occupy 70% or more of the oil-soluble component. Other oil-soluble components are not particularly limited.

界面活性剤は陰イオン界面活性剤、両性イオン界面活性剤、非イオン界面活性剤いずれでもよいが、ステロールエステルの種類や量、その他の油溶性成分、水溶性成分の種類や量によって界面活性剤の種類や量が選択されるが、主に非イオン界面活性剤選択される。
とくに安全性や天然物の利用、皮膚への有効性等の問題よりレシチン、ポリグリセリン脂肪酸エステル、糖セラミドが好ましい。
レシチンは卵黄や植物から抽出されたレシチンはもちろんのこと、これらをさらに精製して得られるレシチンまたは水添物、リゾレシチンを含む。
ポリグリセリン脂肪酸エステルはグリセリンの重合度が5〜15のポリグリセリンと炭素数16〜22の直鎖、分岐、飽和、不飽和の脂肪酸とのエステルで平均エステル化度は2以下であるものがもっともよく利用される。
糖セラミドはガラクトシルセラミド、グルコシルセラミドあるいはこれらを含む動物性スフィンゴ脂質、植物性スフィンゴ脂質等がもっともよく利用される。
The surfactant may be any of an anionic surfactant, an amphoteric surfactant, and a nonionic surfactant. However, depending on the type and amount of sterol ester, other oil-soluble components, and types and amounts of water-soluble components, the surfactant may be used. The type and amount are selected, but the nonionic surfactant is mainly selected.
In particular, lecithin, polyglycerin fatty acid ester, and sugar ceramide are preferable from the viewpoint of safety, utilization of natural products, effectiveness on skin, and the like.
Lecithin includes not only lecithin extracted from egg yolk and plants, but also lecithin or hydrogenated product obtained by further purifying these, and lysolecithin.
Polyglycerol fatty acid ester is an ester of polyglycerol having a polymerization degree of glycerin of 5 to 15 and linear, branched, saturated or unsaturated fatty acid having 16 to 22 carbon atoms and having an average esterification degree of 2 or less. Often used.
As the sugar ceramide, galactosylceramide, glucosylceramide, animal sphingolipids containing these, plant sphingolipids and the like are most often used.

水溶性成分は水、多価アルコール、水溶性薬剤等を配合するが、特に多価アルコールは配合することが好ましい。
多価アルコールは、エチレングリコール、ジエチレングリコール、トリエチレングリコール、それ以上のポリエチレングリコール類、プロピレングリコール、ジプロピレングリコール、それ以上のポリプロピレングリコール類、1,3−ブチレングリコール、1,4−ブチレングリコール等のブチレングリコール類、グリセリン、ジグリセリン、それ以上のポリグリセリン類、ソルビトール、マンニトール、キシリトール、マルチトール等の糖アルコール類、グリセリン類のエチレンオキシド(以下、EOと略記)、プロピレンオキシド(以下、POと略記)付加物、糖アルコール類のEO、PO付加物、ガラクトース、グルコース、フルクトース等の単糖類とそのEO、PO付加物、マルトース、ラクトース等の多糖類とそのEO、PO付加物などの多価アルコール等が例示される。特にこのなかでもグリセリンが本発明の趣旨に合致し、諸条件によって異なるが水溶性成分うち、20%以上はグリセリンであることが好ましい。
多価アルコールは粒子の大きさに影響するので配合量や種類を目的に合致するように選択する。
水もある程度配合可能であるが、微粒子化が必要であるため、後工程で強力な乳化が必要であるので、微粒子化後に水および水溶性薬剤、水溶性高分子等を配合することも可能である。
The water-soluble component contains water, a polyhydric alcohol, a water-soluble drug, etc., but it is particularly preferable to add a polyhydric alcohol.
Polyhydric alcohols include ethylene glycol, diethylene glycol, triethylene glycol, higher polyethylene glycols, propylene glycol, dipropylene glycol, higher polypropylene glycols, 1,3-butylene glycol, 1,4-butylene glycol, etc. Butylene glycols, glycerol, diglycerol, higher polyglycerols, sugar alcohols such as sorbitol, mannitol, xylitol, maltitol, ethylene oxide of glycerol (hereinafter abbreviated as EO), propylene oxide (hereinafter abbreviated as PO) ) Adducts, sugar alcohols EO, PO adducts, saccharides such as galactose, glucose, fructose and their EO, PO adducts, polysaccharides such as maltose, lactose and their EO, with PO Polyhydric alcohol such as object are exemplified. Among these, glycerin is in accordance with the gist of the present invention and varies depending on various conditions, but 20% or more of the water-soluble components are preferably glycerin.
Since the polyhydric alcohol affects the particle size, the blending amount and type are selected so as to meet the purpose.
Although water can be blended to some extent, it is necessary to make fine particles, so strong emulsification is necessary in the subsequent process, so it is also possible to mix water, water-soluble drugs, water-soluble polymers, etc. after fine particle formation. is there.

油溶性成分と、界面活性剤と、水溶性成分の配合比率はそれぞれの種類や製剤の用途、また、以下に述べるように微粒子化後に加える成分や量によって大きく異なるが、油溶性成分を1としたとき、界面活性剤量は0.01〜100、水溶性成分は1〜1000が好ましい。   The blending ratio of the oil-soluble component, surfactant, and water-soluble component varies greatly depending on the type and use of the formulation, and the components and amount added after micronization as described below. The amount of the surfactant is preferably 0.01 to 100, and the water-soluble component is preferably 1 to 1000.

これらの原料を乳化機を使用して、平均粒子径を300nm以下、さらに好ましくは150nm以下に乳化する。
配合原料によってはプロペラ式攪拌機、ホモミキサー等でも可能な場合はあるが、マントンーゴーリン型、マイクロフルイダイザー(商品名、マイクロフルイディスク社製)、アルティマイザー(商品名、タウテクノロジー社製)、ナノマイザー(商品名、ナノマイザー社製)等の高圧乳化機の使用が必要である。
These raw materials are emulsified using an emulsifier to an average particle size of 300 nm or less, more preferably 150 nm or less.
Depending on the ingredients, propeller stirrer, homomixer, etc. may be possible, but Manton-Gorin type, Microfluidizer (trade name, manufactured by Microfluidic), Ultimateizer (trade name, manufactured by Tau Technology), It is necessary to use a high-pressure emulsifier such as Nanomizer (trade name, manufactured by Nanomizer).

乳化後、必要に応じて水溶性成分や水中油型乳化組成物を加えて撹拌し、必要な製剤を得る。
水溶性成分や水中油型乳化組成物には油性成分、保湿剤、界面活性剤、ビタミン類、色素、香料、各種薬剤、水等を配合することができる。
After emulsification, if necessary, a water-soluble component or an oil-in-water emulsion composition is added and stirred to obtain a necessary preparation.
The water-soluble component or the oil-in-water emulsion composition may contain an oil component, a humectant, a surfactant, vitamins, a pigment, a fragrance, various drugs, water, and the like.

以下にその例示をするとオリーブ油、ミンク油、ヒマシ油、パーム油、牛脂、月見草油、ヤシ油、ヒマシ油、カカオ油、マカデミアナッツ油、ホホバ油、ミツロウ、ラノリン、カルナウバロウ、キャンデリラロウ、ラウリルアルコール、ステアリルアルコール、セチルアルコール、オレイルアルコール、ラウリン酸、パルミチン酸、ステアリン酸、固形パラフィン、スクワラン、ワセリン、セレシン、マイクロクリスタリンワックス、ブチルステアレート、ヘキシルラウレート、ジイソプロピルアジペート、ジイソプロピルセバケート、ミリスチン酸オクチルドデシル、イソプロピルミリステート、イソプロピルパルミテートイソプロピルミリステート、セチルイソオクタノエート、ジカプリン酸ネオペンチルグリコール、メチルシリコーン、メチルフェニルシリコーン、エラスチン、コラーゲン、トリクロサン、トリクロロカルバン、メチルパラベン、ブチルパラベン、デオキシリボ核酸及びその塩、アデノシン三リン酸、アデノシン二リン酸、アデノシン一リン酸等のアデニル酸誘導体及びそれらの塩、リボ核酸及びその塩、サイクリックAMP、サイクリックGMP、フラビンアデニンヌクレオチド、グアニン、アデニン、シトシン、チミン、キサンチン及びそれらの誘導体であるカフェイン、テオフィリン、幼牛血液抽出液、血清除蛋白抽出物、脾臓抽出物、トリ等の卵成分、鶏冠抽出物、魚肉抽出物、イカスミ等軟体動物抽出物、ローヤルゼリー、シルクプロテイン及びその分解物又はそれらの誘導体、ヘモグロビン又はその分解物、ラクトフェリン又はその分解物等、哺乳類、鳥類、魚類、軟体動物類、甲殻類、貝類、昆虫類等の動物由来の抽出物;酵母抽出物、乳酸菌抽出物、ビフィズス菌抽出物、醗酵代謝産物等の微生物由来の抽出物;α−及びγ−リノレン酸、エイコサペンタエン酸及びそれらの誘導体、エストラジオール、エテニルエストラジオール等のホルモン類、グリコール酸、クエン酸、乳酸、リンゴ酸、酒石酸、コハク酸、グリチルリチン酸、グリチルレチン酸及びそれらの誘導体並びにそれらの塩、メフェナム酸、フェニルブタゾン、インドメタシン、イブプロフェン、ケトプロフェン、アラントイン、グアイアズレン、パンテノール及びその誘導体並びにそれらの塩、ε−アミノカプロン酸、ジクロフェナクナトリウム、トラネキサム酸あるいは抗酸化剤が、ビタミンA類及びそれらの誘導体並びにそれらの塩、ビタミンB類及びそれらの誘導体並びにそれらの塩、ビタミンD類及びそれらの誘導体並びにそれらの塩、ビタミンE類及びそれらの誘導体並びにそれらの塩、ジブチルヒドロキシトルエン及びブチルヒドロキシアニソール、フェルラ酸とカフェー酸、カロテノイド類、フラボノイド類、タンニン類及び没食子酸及びその塩並びにエステル類、トコフェロール及びその誘導体類、ノニル酸バニリルアミド、カプサイシン、ジンゲロン、カンタリスチンキ、イクタモール、α−ボルネオール、イノシトールヘキサニコチネート、シクランデレート、シンナリジン、トラゾリン、アセチルコリン、ベラパミル、セファランチン、γ−オリザノール、アスコルビン酸及びその誘導体並びにそれらの塩、 N,N’−ジアセチルシスチンジメチル等のシステイン及びその誘導体並びにその塩、グラブリジン、グラブレン、リクイリチン、イソリクイリチン、胎盤抽出物、アルブチン等のハイドロキノン及びその誘導体、レゾルシン及びその誘導体、フェルラ酸とカフェー酸およびそれらの誘導体並びにそれら塩、グルタチオン、蝉退抽出物、カンゾウ抽出物、カミツレ抽出物、カロチノイド類を含有する動植物抽出物、アスパラガス抽出物、エンドウ豆抽出物、エイジツ抽出物、オウゴン抽出物、オノニス抽出物、海藻抽出物、キイチゴ抽出物、クジン抽出物、ケイケットウ抽出物、ゴカヒ抽出物、コーヒー抽出物、コメヌカ抽出物、小麦胚芽抽出物、サイシン抽出物、サンザシ抽出物、サンペンズ抽出物、シラユリ抽出物、シャクヤク抽出物、センプクカ抽出物、大豆抽出物、茶抽出物、糖蜜抽出物、トマト抽出物、ビャクレン抽出物、ブナの芽抽出物、ブドウ抽出物、フローデマニータ抽出物、ホップ抽出物、マイカイカ抽出物、モッカ抽出物、ユキノシタ抽出物、ユーカリ抽出物、ヨクイニン抽出物及び羅漢果抽出物が例示される。(多価アルコールと界面活性剤は前述したので省略する)   Examples are olive oil, mink oil, castor oil, palm oil, beef tallow, evening primrose oil, palm oil, castor oil, cacao oil, macadamia nut oil, jojoba oil, beeswax, lanolin, carnauba wax, candelilla wax, lauryl alcohol, Stearyl alcohol, cetyl alcohol, oleyl alcohol, lauric acid, palmitic acid, stearic acid, solid paraffin, squalane, petrolatum, ceresin, microcrystalline wax, butyl stearate, hexyl laurate, diisopropyl adipate, diisopropyl sebacate, octyldodecyl myristate , Isopropyl myristate, isopropyl palmitate isopropyl myristate, cetyl isooctanoate, neopentyl glycol dicaprate, methyl silicone Methyl phenyl silicone, elastin, collagen, triclosan, trichlorocarban, methyl paraben, butyl paraben, deoxyribonucleic acid and its salts, adenylic acid derivatives such as adenosine triphosphate, adenosine diphosphate, adenosine monophosphate and their salts, ribonucleic acid And salts thereof, cyclic AMP, cyclic GMP, flavin adenine nucleotide, guanine, adenine, cytosine, thymine, xanthine and their derivatives caffeine, theophylline, calf blood extract, serum deproteinized extract, spleen extract , Egg components such as birds, poultry extract, fish meat extract, mollusc extract such as squid, royal jelly, silk protein and its degradation product or their derivatives, hemoglobin or its degradation product, lactoferrin or its degradation product, etc. Extracts from animals such as milk, birds, fish, mollusks, crustaceans, shellfish, insects; extracts from microorganisms such as yeast extract, lactic acid bacteria extract, bifidobacteria extract, fermentation metabolites; α- and γ-linolenic acid, eicosapentaenoic acid and derivatives thereof, hormones such as estradiol, etenyl estradiol, glycolic acid, citric acid, lactic acid, malic acid, tartaric acid, succinic acid, glycyrrhizic acid, glycyrrhetinic acid and their Derivatives and their salts, mefenamic acid, phenylbutazone, indomethacin, ibuprofen, ketoprofen, allantoin, guaiazulene, panthenol and their derivatives and their salts, ε-aminocaproic acid, diclofenac sodium, tranexamic acid or antioxidants are vitamins Class A and their induction Bodies and salts thereof, vitamins B and derivatives thereof, and salts thereof, vitamins D and derivatives thereof, and salts thereof, vitamins E and derivatives thereof, and salts thereof, dibutylhydroxytoluene and butylhydroxyanisole, Ferulic acid and caffeic acid, carotenoids, flavonoids, tannins and gallic acid and salts thereof and esters, tocopherol and derivatives thereof, nonyl acid vanillamide, capsaicin, gingerone, cantalis tincture, ictamol, α-borneol, inositol hexa Nicotinate, cyclandrate, cinnarizine, trazoline, acetylcholine, verapamil, cephalanthin, γ-oryzanol, ascorbic acid and derivatives thereof, and salts thereof, N, N′-diacetylsilane Cysteine such as tin dimethyl and its derivatives and salts thereof, grabridine, glabrene, liquiritin, isoliquiritin, placenta extract, hydroquinone and derivatives thereof such as arbutin, resorcin and derivatives thereof, ferulic acid and caffeic acid and derivatives thereof and salts thereof, Glutathione, deciduous extract, licorice extract, chamomile extract, animal and plant extract containing carotenoids, asparagus extract, pea extract, age extract, oxon extract, onionis extract, seaweed extract, Raspberry extract, Kujin extract, Caiquet extract, Gokahi extract, Coffee extract, Rice bran extract, Wheat germ extract, Saisin extract, Hawthorn extract, Sunpens extract, Shirayuri extract, Peonies extract, Sempukuka Extract, soy Extract, tea extract, molasses extract, tomato extract, beechlen extract, beech bud extract, grape extract, flow demanita extract, hop extract, micaika extract, mokka extract, yukinoshita extract And Eucalyptus extract, Yokuinin extract, and Luohan fruit extract. (The polyhydric alcohol and the surfactant are omitted because they are described above.)

製剤の形態としては、特に限定されず、例えば、乳液、クリーム、水溶液、パック等の任意の剤形を選択することができる。   It does not specifically limit as a form of a formulation, For example, arbitrary dosage forms, such as a milky lotion, cream, aqueous solution, a pack, can be selected.

実施例1 重量部
A部
水素添加レシチン 0.500
グリセリン 13.200
1,3ブチレングリコール 3.300
B部
オレイン酸ジヒドロコレステリル 0.761
ノナン酸コレステリル 0.761
酪酸コレステリル 0.453
酪酸ジヒドロコレステリル 0.305
オレイン酸フィトステアリル 0.120
長鎖分岐脂肪酸コレステリル 0.600
作成方法
A部、B部をそれぞれ撹拌しながら85℃で溶解した。A部にB部を加えながらホモジナイザー(プライミクス社製 型番T.K.ロボミックス)5000rpmで1分間撹拌した。
これをマイクロフルイダイザー(マイクロフルイディスク社製型番M−110−EH)124MPaで1回処理した。
これを35℃まで徐冷した。
なお、水素添加レシチンは(辻製油社製SLP−PC70HS)を長鎖分岐脂肪酸コレステリルは日本精化社製YOFCO CLE−NEを用いた。
Example 1 Part A by weight
Hydrogenated lecithin 0.500
Glycerin 13.200
1,3-butylene glycol 3.300
B part dihydrocholesteryl oleate 0.761
Cholesteryl nonanoate 0.761
Cholesteryl butyrate 0.453
Dihydrocholesteryl butyrate 0.305
Phytostearyl oleate 0.120
Long-chain branched fatty acid cholesteryl 0.600
Preparation method Part A and part B were dissolved at 85 ° C. with stirring. While adding part B to part A, the mixture was stirred at 5000 rpm for 1 minute with a homogenizer (Model No. TK Robotics, manufactured by Primics).
This was treated once with a microfluidizer (model number M-110-EH manufactured by Microfluidic Corporation) of 124 MPa.
This was gradually cooled to 35 ° C.
The hydrogenated lecithin (SLP-PC70HS manufactured by Sakai Oil Co., Ltd.) was used, and the long-chain branched fatty acid cholesteryl used was Nippon Seika Co., Ltd. YOFCO CLE-NE.

実施例2 重量部
実施例1 20.0
精製水 58.4
1,3ブチレングリコール 4.7
1,2ペンタンジオール 3.0
パラオキシ安息香酸メチル 0.1
グリセリン 1.8
2%カルボキシビニルポリマー水溶液(中和) 12.0
作成方法
これらを混合した。
Example 2 parts by weight Example 1 20.0
Purified water 58.4
1,3 butylene glycol 4.7
1,2 pentanediol 3.0
Methyl paraoxybenzoate 0.1
Glycerin 1.8
2% carboxyvinyl polymer aqueous solution (neutralized) 12.0
Production method These were mixed.

実施例3 重量部
A部
スクワラン 15.0
オリーブ油 1.0
ミンク油 1.0
ホホバ油 2.0
ミツロウ 2.0
セトステアリルアルコール 2.0
グリセリンモノステアレート 1.0
ソルビタンモノステアレート 2.0
B部
精製水 37.9
ポリオキシエチレン(20E.O.)ソルビタンモノステアレート 2.0
ポリオキシエチレン(60E.O.)硬化ヒマシ油 1.0
グリセリン 5.0
1.0%ヒアルロン酸ナトリウム水溶液 5.0
パラオキシ安息香酸メチル 0.1
C部
実施例1 20.0
A部とB部をそれぞれ計量し、70℃まで加温し、B部にA部を撹拌しつつ徐々に加えたのち、ゆっくり撹拌しつつ30℃まで冷却した。これにC部を撹拌しつつ徐々に加えた
Example 3 Part by weight Part A squalane 15.0
Olive oil 1.0
Mink oil 1.0
Jojoba oil 2.0
Beeswax 2.0
Cetostearyl alcohol 2.0
Glycerol monostearate 1.0
Sorbitan monostearate 2.0
Part B
Purified water 37.9
Polyoxyethylene (20E.O.) sorbitan monostearate 2.0
Polyoxyethylene (60E.O.) hydrogenated castor oil 1.0
Glycerin 5.0
1.0% sodium hyaluronate aqueous solution 5.0
Methyl paraoxybenzoate 0.1
Part C Example 1 20.0
Part A and part B were weighed and heated to 70 ° C., part A was gradually added to part B with stirring, and then cooled to 30 ° C. with slow stirring. To this, part C was gradually added with stirring.

比較例1
マイクロフルイダイザー処理のみを省略した実施例1を用いた実施例2で、他は同一のもの
Comparative Example 1
Example 2 using Example 1 in which only the microfluidizer process is omitted, the others are the same

皮膚バリア機能回復促進試験
健常男子(34〜54才)6名で以下の試験を実施した。
左前腕内側部3ヶ所に内径2cmのガラス円筒を押し付けでガラス円筒に1%ラウリル硫酸ナトリウム水溶液を5ml入れ、5分間放置後取り除いた。これを1日2回、3日間実施した。
ラウリル硫酸ナトリウムで肌荒れを起こした部位に、検体1(実施例2)、検体2(比較例1)、を1日2回、25日間塗布した。(1ヶ所は無塗布)
ラウリル硫酸ナトリウムで肌荒れを起こす前(初期)、ラウリル硫酸ナトリウムを6回塗布後、検体塗布後4日後、11日後、18日後、25日後に以下の方法で皮膚からの水分蒸発量(TEWL)を測定した。
左前腕内側部を市販の洗顔フォームで洗浄した後、温度21℃±2℃、湿度45%±5%の恒温恒湿室で30分間経過後、水分蒸発量(TEWL)を測定した。
測定にはアサヒバイオメッド社製VAPOSCAN AS−VT100RSを用いた。
結果は6名の平均を取り、初期値を1として示した。(表1)
Skin barrier function recovery promotion test The following tests were carried out by 6 healthy men (34 to 54 years old).
A glass cylinder with an inner diameter of 2 cm was pressed against the three inner parts of the left forearm. This was carried out twice a day for 3 days.
Specimen 1 (Example 2) and Specimen 2 (Comparative Example 1) were applied twice a day for 25 days to the site of rough skin caused by sodium lauryl sulfate. (No application at one place)
Before causing skin irritation with sodium lauryl sulfate (initial), after applying sodium lauryl sulfate 6 times, 4 days, 11 days, 18 days, and 25 days after applying the sample, the amount of water evaporation (TEWL) from the skin was measured as follows. It was measured.
After washing the inner part of the left forearm with a commercially available facial cleansing foam, the amount of water evaporation (TEWL) was measured after 30 minutes in a constant temperature and humidity chamber at a temperature of 21 ° C. ± 2 ° C. and a humidity of 45% ± 5%.
For measurement, VAPOSCAN AS-VT100RS manufactured by Asahi Biomed Co., Ltd. was used.
As a result, an average of 6 persons was taken and the initial value was shown as 1. (Table 1)

Figure 2010024180
Figure 2010024180

粒子径の測定
実施例1及び比較例1で用いたマイクロフルイダイザー処理を省略した実施例1と同一処方部の1%水溶液をマルバーン社製ゼータサイザーナノで粒子径を測定した結果、平均粒子径は、実施例1が133nm、比較例1で用いたマイクロフルイダイザー処理を省略した実施例1と同一処方部で2970nmであった。
Measurement of particle diameter As a result of measuring the particle diameter of a 1% aqueous solution of the same prescription part as in Example 1 in which microfluidizer treatment used in Example 1 and Comparative Example 1 is omitted with Zetasizer Nano manufactured by Malvern, the average particle diameter Was 133 nm in Example 1 and 2970 nm in the same prescription part as Example 1 in which the microfluidizer treatment used in Comparative Example 1 was omitted.

このように、実施例2と比較例1は同一配合物であるにも関わらず、平均粒子径が異なることによって肌荒れの改善すなわち、皮膚バリア機能の回復をすみやかに行うことがわかった。   Thus, although Example 2 and Comparative Example 1 were the same composition, it turned out that an average particle diameter differs and the rough skin improvement, ie, the recovery | restoration of a skin barrier function, is performed rapidly.

Claims (5)

ステロールエステルを70%以上含む油溶性成分と、界面活性剤の1種または2種以上と、水溶性成分からなる乳化物で、平均粒子径が300nm以下である皮膚バリア機能回復促進用水中油型乳化組成物   An oil-in-water emulsified emulsion for promoting the recovery of skin barrier function having an average particle size of 300 nm or less, comprising an oil-soluble component containing 70% or more of a sterol ester, one or more surfactants, and a water-soluble component. Composition 界面活性剤が、レシチン、ポリグリセリン脂肪酸エステル、糖セラミドより選択された1種または2種以上である請求項1の皮膚バリア機能回復促進用水中油型乳化組成物    The oil-in-water emulsion composition for promoting skin barrier function recovery according to claim 1, wherein the surfactant is one or more selected from lecithin, polyglycerin fatty acid ester and sugar ceramide. ステロールエステルの一部が分岐脂肪酸(炭素数12〜31)とコレステロールのエステルである請求項1乃至請求項2の皮膚バリア機能回復促進用水中油型乳化組成物   The oil-in-water emulsion composition for promoting the recovery of skin barrier function according to claim 1 or 2, wherein a part of the sterol ester is an ester of a branched fatty acid (12 to 31 carbon atoms) and cholesterol. 平均粒子径が150nm以下である請求項1乃至請求項3の皮膚バリア機能回復促進用水中油型乳化組成物   4. The oil-in-water emulsion composition for promoting the recovery of skin barrier function according to claim 1, wherein the average particle size is 150 nm or less. 請求項1乃至請求項3の水中油型乳化組成物に水溶性成分および/または水中油型乳化組成物を加えた皮膚バリア機能回復促進用組成物   A composition for promoting the recovery of skin barrier function, wherein a water-soluble component and / or an oil-in-water emulsion composition is added to the oil-in-water emulsion composition of claims 1 to 3.
JP2008187103A 2008-07-18 2008-07-18 Oil-in-water emulsified composition for promoting skin barrier function recovery Active JP5642924B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2008187103A JP5642924B2 (en) 2008-07-18 2008-07-18 Oil-in-water emulsified composition for promoting skin barrier function recovery

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2008187103A JP5642924B2 (en) 2008-07-18 2008-07-18 Oil-in-water emulsified composition for promoting skin barrier function recovery

Publications (2)

Publication Number Publication Date
JP2010024180A true JP2010024180A (en) 2010-02-04
JP5642924B2 JP5642924B2 (en) 2014-12-17

Family

ID=41730324

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008187103A Active JP5642924B2 (en) 2008-07-18 2008-07-18 Oil-in-water emulsified composition for promoting skin barrier function recovery

Country Status (1)

Country Link
JP (1) JP5642924B2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010254670A (en) * 2009-03-31 2010-11-11 Kose Corp Oil-in-water emulsion cosmetic
US10703913B2 (en) 2015-12-25 2020-07-07 Shiseido Company, Ltd. Titanium dioxide powder and cosmetic formulated therewith

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5670826A (en) * 1979-11-15 1981-06-13 Nippon Saafuakutanto Kogyo Kk Oil-in-polyhydric alcohol type emulsion composition
JPS591407A (en) * 1983-06-02 1984-01-06 Kao Corp Cosmetic containing branched fatty acid cholesteryl ester
JPS6253910A (en) * 1985-09-02 1987-03-09 Kao Corp Liquid crystal-type oily cosmetic
JPH08183726A (en) * 1994-12-28 1996-07-16 Kose Corp Skin preparation for external use
JPH09132512A (en) * 1995-09-06 1997-05-20 Nippon Fine Chem Co Ltd Lamellar structure of sterol fatty acid ester
JPH09157131A (en) * 1995-12-14 1997-06-17 Kira Keshohin Kk Emulsified composition
JPH101413A (en) * 1996-06-11 1998-01-06 Noevir Co Ltd Cosmetic
WO2002078650A1 (en) * 2001-03-29 2002-10-10 The Nisshin Oillio, Ltd. Cosmetic emulsion preparation and agent for external use
JP2006089420A (en) * 2004-09-24 2006-04-06 Yoshida Kikai Co Ltd Emulsification type cosmetic

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5670826A (en) * 1979-11-15 1981-06-13 Nippon Saafuakutanto Kogyo Kk Oil-in-polyhydric alcohol type emulsion composition
JPS591407A (en) * 1983-06-02 1984-01-06 Kao Corp Cosmetic containing branched fatty acid cholesteryl ester
JPS6253910A (en) * 1985-09-02 1987-03-09 Kao Corp Liquid crystal-type oily cosmetic
JPH08183726A (en) * 1994-12-28 1996-07-16 Kose Corp Skin preparation for external use
JPH09132512A (en) * 1995-09-06 1997-05-20 Nippon Fine Chem Co Ltd Lamellar structure of sterol fatty acid ester
JPH09157131A (en) * 1995-12-14 1997-06-17 Kira Keshohin Kk Emulsified composition
JPH101413A (en) * 1996-06-11 1998-01-06 Noevir Co Ltd Cosmetic
WO2002078650A1 (en) * 2001-03-29 2002-10-10 The Nisshin Oillio, Ltd. Cosmetic emulsion preparation and agent for external use
JP2006089420A (en) * 2004-09-24 2006-04-06 Yoshida Kikai Co Ltd Emulsification type cosmetic

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
フレグランスジャーナル, vol. 27, no. 1, JPN6014025901, 15 January 1999 (1999-01-15), pages 94 - 100, ISSN: 0002838441 *
機能性化粧品IV, JPN6012057973, 30 June 2006 (2006-06-30), pages 264 - 269, ISSN: 0002377404 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010254670A (en) * 2009-03-31 2010-11-11 Kose Corp Oil-in-water emulsion cosmetic
US10703913B2 (en) 2015-12-25 2020-07-07 Shiseido Company, Ltd. Titanium dioxide powder and cosmetic formulated therewith

Also Published As

Publication number Publication date
JP5642924B2 (en) 2014-12-17

Similar Documents

Publication Publication Date Title
TWI652107B (en) Method for forming dispersion and hydrogel
JP2008280271A (en) Agent for preventing photoaging of skin
JP2005220084A (en) Acerola seed extract-containing composition
JP2006257064A (en) Lipid absorption-suppressing composition
CN113226277A (en) Whitening agent, hyaluronic acid production promoter, collagen production promoter, intracellular active oxygen scavenger, irritation relieving agent, wrinkle improving agent, complex, cosmetic and skin external preparation
JP2008280311A (en) Prophylactic/curative agent for hyperlipemia
JP2008189571A (en) New therapeutic or prophylactic agent for diabetes and/or obesity
CN107427440A (en) Moisturizing base material containing lipid peptide type compound
JP2001002551A (en) Agent for increasing hyaluronic acid content of horny layer
JP2007297343A (en) Lipid metabolism improver
JP4707997B2 (en) L-ascorbic acid-2-phosphate magnesium sodium salt, process for producing the same, and cosmetics containing the salt
JP6234112B2 (en) W / O / W emulsion composition
JP5642924B2 (en) Oil-in-water emulsified composition for promoting skin barrier function recovery
JP2007063207A (en) Adiponectin production promoter
JP5230965B2 (en) Emulsified composition
CN107708660A (en) Include the bar-shaped base material of lipid peptide type compound
JP2003226632A (en) Skin cosmetic and food and beverage for beauty
JP4201091B1 (en) Moisturizer, anti-aging agent, antioxidant and external preparation for skin
JP2018048103A (en) Skin quality improving agent
JP2007063206A (en) Neutral fat-accumulation inhibitor
JP4703809B2 (en) Topical skin preparation
JP2011016767A (en) Moisturizer
JP2004107242A (en) Kit for improving dry skin
JP2004107238A (en) Kit for improving dry skin
JP2019131490A (en) Oil-in-water type emulsion cosmetic

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110510

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20121029

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130827

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131001

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140624

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140822

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20140829

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20141028

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20141030

R150 Certificate of patent or registration of utility model

Ref document number: 5642924

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250